Drug survival 'poor' for most patients on thalidomide

The exception appears to be treatment for actinic prurigo, Melbourne dermatologists say

Most patients prescribed thalidomide for a dermatological condition other than actinic prurigo cease the therapy within two years, according to an Australian case series.

thalidomide molecular structure

Victorian dermatologists describe outcomes for 28 dermatology patients treated with thalidomide at a large Melbourne hospital in a research letter to the Australasian Journal of Dermatology.

The patients had a range of dermatoses that were recalcitrant to other therapies, including actinic prurigo, cutaneous lupus erythematosus, prurigo